Torrent Pharma Share Price: 32.6% CAGR in 3 Years as the Ahmedabad Drug Maker Beats Zydus, Lupin and Sun Pharma

Torrent Pharma previous close Rs 4,780. 3-year CAGR 32.6%. Up 2.3x since 9 Nov 2023. ROE 11.42%. Market cap Rs 1,81,626 crore.

The Torrent Pharma share price has more than doubled in three years, and that makes Torrent Pharmaceuticals the best performer among large listed pharma companies in this comparison. The Ahmedabad-based company is known for its strength in chronic therapies such as cardiac, diabetes and central nervous system medicines.

This article compares that run with Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries. We calculate the three-year CAGR for all four and set the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.

Click Here – Get Free Investment Predictions

How Much Has the Torrent Pharma Share Price Returned in 3 Years?

The Torrent Pharma stock closed at Rs 2,051.20 on 9 November 2023 and at Rs 4,780.00 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 2.33 lakh, which is a CAGR of 32.6%. This is a price return and leaves out dividends.

CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Torrent Pharma can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.

The Torrent Pharma share price has also been helped by growth in the Indian branded medicines market, where chronic therapy prescriptions tend to repeat month after month.

Torrent Pharma vs Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries: 3-Year CAGR Compared

The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.

Company	Close on 9 Nov 2023	Previous close (9 Nov 2026)	Price multiple	3-year CAGR
Torrent Pharmaceuticals	Rs 2,051.20	Rs 4,780.00	2.3x	32.6%
Zydus Lifesciences	Rs 612.45	Rs 1,215.90	2.0x	25.7%
Lupin	Rs 1,204.55	Rs 2,025.00	1.7x	18.9%
Sun Pharmaceutical Industries	Rs 1,176.20	Rs 1,904.50	1.6x	17.4%

The Torrent Pharma stock leads the group at 32.6%, followed by Zydus Lifesciences at 25.7%, Lupin at 18.9% and Sun Pharmaceutical Industries at 17.4%. Torrent Pharma leads the group, followed by Zydus, Lupin and Sun Pharma. Sun Pharma is the largest of the four by market cap, while Torrent ranks second, so its return came on a large base of capital.

Look at the Torrent Pharma share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.

Valuation and Quality Compared

Company	Market cap	P/E	Industry P/E	ROE	Debt to equity
Sun Pharmaceutical Industries	Rs 4,57,073 crore	41.60	40.13	13.79%	0.04
Torrent Pharmaceuticals	Rs 1,81,626 crore	86.53	40.13	11.42%	0.77
Zydus Lifesciences	Rs 1,21,002 crore	28.13	40.13	15.10%	0.50
Lupin	Rs 92,007 crore	17.62	40.13	21.65%	0.26

By market cap, Sun Pharmaceutical Industries is the largest of the group at Rs 4,57,073 crore, while the Torrent Pharma stock stands at Rs 1,81,626 crore, about 40% of that size. On earnings, Torrent Pharma shares trade at a P/E of 86.53 against an industry P/E of 40.13, a premium of about 116%, which signals that the market expects faster earnings growth. Peer multiples are Zydus Lifesciences at 28.13, Lupin at 17.62 and Sun Pharmaceutical Industries at 41.60.

Return on equity is 11.42% for the Torrent Pharma stock, which ranks fourth among the four, and debt to equity stands at 0.77. Trailing EPS is Rs 55.18. Pharma companies with a strong branded business often trade at a premium, so the P/E should be read next to return on equity and the pace of earnings growth.

What Is Driving the Torrent Pharma Stock?

Torrent Pharmaceuticals earns most of its revenue from branded generics in India and from markets such as Brazil and Germany. Chronic therapy brands bring repeat prescriptions, which supports revenue visibility.

The company has widened its Indian portfolio through acquisitions and new launches. A larger field force and a stronger presence in dermatology and other segments add more room for growth.

Followers of the Torrent Pharma share price usually track growth in the India business, the performance of international markets, integration of acquired brands and operating margins.

How the Established Players Stack Up

Zydus Lifesciences is an Ahmedabad-based drug maker with generics, specialty and vaccine businesses and a strong presence in the United States. It compounded at 25.7% a year, on a market cap of Rs 1,21,002 crore and an ROE of 15.10%.

Lupin is a Mumbai-based pharma company with strength in respiratory, cardiac and anti-infective medicines and a large export business. It compounded at 18.9% a year, on a market cap of Rs 92,007 crore and an ROE of 21.65%.

Sun Pharmaceutical Industries is India's largest drug maker by sales, with a growing specialty portfolio and a large presence in India and the United States. It compounded at 17.4% a year, on a market cap of Rs 4,57,073 crore and an ROE of 13.79%.

What Should Investors Track Next?

Three things are worth watching on the Torrent Pharma share price. First, growth of the India branded business. Second, the contribution from acquired brands. Third, margins as the product mix changes.

At a P/E of 87, expectations are very high, since the multiple is more than double the industry P/E of 40.13. A premium of that size leaves less room for an earnings miss.

Check the Univest Screener for live fundamentals of pharma stocks

How to Compare Pharma Stocks Yourself

You can repeat this exercise for any pair of stocks, including the Torrent Pharma stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.

A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Torrent Pharma share price, the same four checks give a more complete picture than price alone.

Download the Univest iOS App or Univest Android App to track the Torrent Pharma share price and compare pharma stocks live.

A Fast Compounder Trading at a Steep Premium

The Torrent Pharma share price compounded at 32.6% a year over three years, ahead of Zydus at 25.7%, Lupin at 18.9% and Sun Pharma at 17.4%. Its ROE is 11.42% and its P/E is the highest in the group.

Lupin brings a higher ROE with a lower multiple, Zydus brings a broader mix, and Sun Pharma brings scale. The choice depends on how much valuation premium you are comfortable paying.

Frequently Asked Questions

What is the Torrent Pharma share price today?

Ans. Torrent Pharmaceuticals closed at Rs 4,780 on 9 November 2026, according to NSE data. It has a market cap of Rs 1,81,626 crore and a P/E of 86.53. Check live quotes before acting, as prices change every trading day.

What is the 3-year CAGR of the Torrent Pharma stock?

Ans. Torrent Pharmaceuticals delivered a price CAGR of 32.6% over three years, moving from Rs 2,051.20 on 9 November 2023 to Rs 4,780.00 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.

Is Torrent Pharma better than Sun Pharma?

Ans. Torrent Pharma delivered a higher three-year CAGR at 32.6% than Sun Pharma at 17.4%. Sun Pharma trades at a lower P/E of 41.60 against 86.53 and has a market cap of Rs 4,57,073 crore. The better choice depends on your view of each business.

What does Torrent Pharmaceuticals do?

Ans. Torrent Pharmaceuticals is an Ahmedabad-based drug maker with a strong branded generics business in India and operations in Brazil, Germany and other markets.

Is the Torrent Pharma stock debt free?

Ans. The debt to equity ratio of the Torrent Pharma stock is 0.77 and its return on equity is 11.42%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.

Is Torrent Pharma expensive compared with the industry?

Ans. Torrent Pharma trades at a P/E of 86.53 against an industry P/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.

Which pharma stock gave the highest return in 3 years?

Ans. Among the companies compared here, Torrent Pharmaceuticals delivered the highest three-year CAGR at 32.6%, followed by Zydus Lifesciences at 25.7%. Past returns do not guarantee future performance.

How do I calculate CAGR for a stock?

Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.